Label For One: FDA Explores Taking Reservations For Brand Names
This article was originally published in The Tan Sheet
Executive Summary
Request for information indicates agency’s approach to allow sponsors to hold proprietary names pre-approval may still be too tepid for industry.
You may also be interested in...
Draft Guidance On Developing Drug Names Calls For Simulation Studies
FDA’s draft guidance on developing proprietary drug names recommends steps to evaluate a proposed name, including testing names with health care professionals. The draft notes that OTC “brand name extensions have posed problems when the same root proprietary name is used for multiple products.”
What’s In A Name? Janssen’s Loss Of Sovriad Was Gilead’s Gain With Sovaldi
FDA initially rejected both sponsors’ preferred proprietary names for their hepatitis C treatments due to the risk of confusion with each other. Janssen had to settle for Olysio, its backup name for simeprevir, leaving Gilead to claim title to its preferred name for sofosbuvir.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.